CLINICAL_TRIALS ClinicalTrials.gov record update

480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00953589
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:13.581166+00:00
Published At: 2012-02-02T00:00:00+00:00
Record Updated At: 2012-02-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hepatitis C, Chronic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-02-02"
protocolSection.identificationModule.nctId: "NCT00953589"
protocolSection.identificationModule.officialTitle: "480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Na\u00efve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 \u00b5g Dose of Locteron\u2122 Plus Ribavirin Given Bi-Weekly to PEG-Intron\u2122 Plus Ribavirin Given Weekly"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.